Circulating Methylated- <i>DCR2</i> Gene in Serum as an Indicator of Prognosis and Therapeutic Efficacy in Patients with <i>MYCN</i> Nonamplified Neuroblastoma

Abstract

Detection of methylated-DCR2 in serum DNA has promise as a noninvasive assay for predicting prognosis and therapeutic efficacy in neuroblastoma, especially in non-MNA cases. Furthermore, it might be a sensitive marker of tumor recurrence in DCR2-methylated cases.